Treatment of neuroblastoma with [125I]metaiodobenzylguanidine.
To find a treatment that may be effective against micrometastases of advanced, stage III or IV neuroblastoma, [125I]metaiodobenzylguanidine (125I-MIBG) was used in a phase I toxicity trial. In seven patients, thrombocytopenia was encountered with absorbed whole body doses of 85-135 rad from 125I-MIBG, but the dosimetry was imprecise in predicting bone marrow injury. Three patients survived for over one year, results that may indicate efficacy of 125I-MIBG therapy.
Sisson
J C
JC
Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0028.
Shapiro
B
B
Hutchinson
R J
RJ
Zasadny
K R
KR
Mallette
S
S
Mudgett
E E
EE
Wieland
D M
DM
D019797:3-Iodobenzylguanidine; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D009447:Neuroblastoma / Q000628:therapy*; D013921:Thrombocytopenia / Q000209:etiology
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine